POSC325 Use of the New French ‘Organizational Impact Map’ Published by the Haute Autorité de Santé (HAS) to Evaluate the Organizational Impact of Immune-Checkpoint Inhibitors in Advanced Cancers

V Grumberg,C Chouaid,Fe Cotte,Af Gaudin,I Borget

doi:10.1016/j.jval.2021.11.1036

POSC325 Use of the New French ‘Organizational Impact Map’ Published by the Haute Autorité de Santé (HAS) to Evaluate the Organizational Impact of Immune-Checkpoint Inhibitors in Advanced Cancers

V Grumberg, C Chouaid + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.1036

Copy DOI

Journal: Value in Health	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Bristol-Myers Squibb (France), Institut Gustave Roussy, University of Paris-Saclay, Institut Polytechnique de Paris, La Ligue Contre le Cancer, Inserm

#Haute Autorité De Santé #Immune-Checkpoint Inhibitors In Advanced Cancers + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

HAS defined an organizational impact (OI) as an effect, consequence, result, repercussion created by a health technology on the characteristics and functioning of an organization or a set of organizations involved in the care of users. In 2021, HAS has published an ‘Organizational Impact Map’, to evaluate the OI of health products. As immune-checkpoint inhibitors (ICI) have considerably modified management of cancer patients, the objective is to assess OIs of ICIs in advanced cancers care in France.

Full Text